Man sues GLP-1 drug maker after sudden, permanent blindness linked to Ozempic
सिर्फ तथ्य

Man sues GLP-1 drug maker after sudden, permanent blindness linked to Ozempic

सारांश

A Massachusetts father claims the diabetes medication Ozempic caused sudden, irreversible vision loss, joining more than 200 similar lawsuits against GLP-1 drug manufacturers.

A 59-year-old Massachusetts resident who uses the diabetes medication Ozempic says he lost his sight within weeks after the drug was prescribed, and has filed a lawsuit against its maker. The man, a father of four and former softball coach, reported noticing a speck in his eye in early May and becoming completely blind by June 1. Medical examinations diagnosed non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition that blocks blood flow to the optic nerve and can cause permanent vision loss.

"You don't accept it. You don't believe it. You're just, 'What the heck is going on?'"

He is now among more than 200 plaintiffs alleging that GLP-1 drugs such as semaglutide, sold under brand names including Ozempic, Wegovy and Rybelsus, caused NAION. Studies published in 2024 identified a statistical association between semaglutide use and an increased risk of the condition, though researchers emphasized that the overall risk remains low. Professional societies have noted that patients taking GLP-1 drugs often have pre-existing risk factors for NAION, such as diabetes, obesity, hypertension and sleep apnea, complicating causal assessments.

The lawsuits target Novo Nordisk, the manufacturer of Ozempic and related products, and Eli Lilly, which produces other GLP-1 medications. Plaintiffs argue that the companies failed to adequately warn users about the potential vision-loss risk and that the drugs are defectively dangerous.

"Novo believes the personal injury lawsuits filed in the U.S. are without merit and we are defending them in court," said Liz Skrbkova, head of U.S. media and stakeholder relations at Novo Nordisk. She added that patient safety is a top priority and that semaglutide has a well-established safety profile based on extensive clinical and post-marketing data.

The legal actions highlight ongoing concerns about rare side effects of GLP-1 therapies, even as the drugs remain widely prescribed for type 2 diabetes and obesity.

स्रोत

Yahoo

पढ़ते रहें — निःशुल्क

समाचार फ़ॉलो करने के लिए मुफ़्त खाता बनाएँ। कार्ड की आवश्यकता नहीं।